Nuvation Bio Halts Development of BET Inhibitor NUV-868 Following Interim Phase 1 Data Review

Decision Basis::
Nuvation Bio has decided to pause the development of its BET inhibitor, NUV-868, after a careful review of interim data from Phase 1 studies.

Phase 1 Studies::
The decision was made based on data from both the Phase I monotherapy study and the Phase 1b study of NUV-868 in combination with other treatments.

Drug Candidate::
NUV-868 was being investigated for the treatment of solid tumors.

Future Plans::
The company will not proceed with a Phase 2 trial for NUV-868 at this time.

Reason for Pause::
The pause is due to the analysis of safety and efficacy data from the Phase 1 studies, which did not meet the expected outcomes.